Therapeutic targeting of c-KIT in cancer

Advances in Adjuvant Therapy of Gastrointestinal Stromal Tumors

(2012) K. Adekola et al.   Current Oncology Reports

Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management

(2011) Animesh Pardanani   AMERICAN JOURNAL OF HEMATOLOGY

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

(2011) Dian Wang et al.   ANNALS OF SURGICAL ONCOLOGY

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice

(2011) L. Zhao et al.   BLOOD

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

(2011) K. V. Gleixner et al.   BLOOD

The clinical development of FLT3 inhibitors in acute myeloid leukemia

(2011) Steven Knapper   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study

(2011) Simone Muenst et al.   HUMAN PATHOLOGY

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reactivating PP2A by FTY720 as a Novel therapy for AML with C-KIT tyrosine kinase domain mutation

(2011) Yan Yang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib

(2011) Edward J. Kim et al.   JOURNAL OF SURGICAL ONCOLOGY

Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia

(2011) Sang Hyuk Park et al.   LEUKEMIA RESEARCH

The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors

(2011) G. Floris et al.   MOLECULAR CANCER THERAPEUTICS

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

(2011) Y.-Y. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Colony stimulating factor-1 receptor as a target for small molecule inhibitors

(2010) Baratali Mashkani et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

(2010) J. A. Pollard et al.   BLOOD

A phase 2 trial of dasatinib in advanced melanoma

(2010) Harriet M. Kluger et al.   CANCER

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers

(2010) K. G. Roberts et al.   CANCER RESEARCH

Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature

(2010) Animesh Pardanani et al.   CURRENT OPINION IN HEMATOLOGY

Kitlow Stem Cells Cause Resistance to Kit/Platelet-Derived Growth Factor α Inhibitors in Murine Gastrointestinal Stromal Tumors

(2010) Michael R. Bardsley et al.   GASTROENTEROLOGY

Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance

(2010) J. P. DiNitto et al.   JOURNAL OF BIOCHEMISTRY

Role for the Proapoptotic Factor BIM in Mediating Imatinib-induced Apoptosis in a c-KIT-dependent Gastrointestinal Stromal Tumor Cell Line

(2010) Peter M. Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients

(2010)   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

(2010) Axel Le Cesne et al.   LANCET ONCOLOGY

Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells

(2010) David Reynoso et al.   Molecular Oncology

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours

(2010) Ping Chi et al.   NATURE

Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)

(2010) A. Gupta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine

(2009) Ken H. Lim et al.   AMERICAN JOURNAL OF HEMATOLOGY

Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance

(2009) T. Guo et al.   CLINICAL CANCER RESEARCH

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene

(2009) Toshirou Nishida et al.   International Journal of Clinical Oncology

The D816V Mutation of c-Kit Circumvents a Requirement for Src Family Kinases in c-Kit Signal Transduction

(2009) Jianmin Sun et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

(2009) Arturo Vega-Ruiz et al.   LEUKEMIA RESEARCH

Activate and resist: L576P-KIT in GIST

(2009) E. Conca et al.   MOLECULAR CANCER THERAPEUTICS

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2009) S. E. Woodman et al.   MOLECULAR CANCER THERAPEUTICS

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

(2009) K. S. Gajiwala et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

Dasatinib therapy for systemic mastocytosis: four cases

(2008) Duncan Purtill et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation

(2008) Stéphanie Kermorgant et al.   JOURNAL OF CELL BIOLOGY

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY